Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects

Next Previous
X
Search
Trial Profile

Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aceclidine (Primary) ; Aceclidine/brimonidine (Primary)
  • Indications Presbyopia
  • Focus Adverse reactions; Registrational
  • Acronyms CLARITY-3
  • Sponsors LENZ Therapeutics

    • Most Recent Events

    • 02 Apr 2024 According to a LENZ Therapeutics media release, The Company will host a conference call and webcast today, Wednesday, April 3, 2024, at 8:00 a.m. ET to discuss the topline results
    • 02 Apr 2024 Topline Results presented in the LENZ Therapeutics Media Release
    • 21 Mar 2024 According to a LENZ Therapeutics media release, the company is looking forward to reporting topline results from these trials in April 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top